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Abstract The purpose of this study was to assess the phar-
macokinetic (PK) characteristics, clinical efficiency, and
pharmacoeconomic parameters of piperacillin/tazobactam ad-
ministered by extended infusion (EI) or intermittent infusion
(II) in the treatment of hospital-acquired pneumonia (HAP) in
critically ill patients with low illness severity in China. Fifty
patients completed the study, with 25 patients receiving
4/0.5 g piperacillin/tazobactam over 30 min as the II group
and 25 patients receiving 4/0.5 g piperacillin/tazobactam over
3 h every 6 h as the EI group. Drug assay was performed using
high-performance liquid chromatography (HPLC). The per-
centage of the dosing interval for which the free piperacillin
concentration (%fT) exceeds the minimum inhibitory concen-
tration (MIC) was calculated. The patients’ therapy cost, clin-
ical efficiency, and adverse effects were also recorded.
%fT>MIC was about 100, 98.73, and 93.04 % in the EI arm
versus 81.48, 53.29, and 42.15 % in the II arm, respectively,
when the microorganism responsible for HAP had an MIC of
4, 8, and 16 mg/L. The therapy cost in the EI group was lower
than that of the II group ($1351.72 ± 120.39 vs. $1782.04
± 164.51, p = 0.001). However, the clinical success rate,
clinical failure rate, and drug-related adverse events did not
significantly differ between groups. EI treatment with
piperacillin/tazobactam was a cost-effective approach to the
management of HAP, being equally clinically effective to con-
ventional II.
Introduction
Hospital-acquired pneumonia (HAP) accounts for about 15 %
of all hospital-acquired infections (HAI) and is associatedwith
high morbidity and mortality [1]. Approximately 10 to 50 %
of patients treated for nosocomial pneumonia develop antimi-
crobial resistance [2]. The emergence of multidrug-resistant
Gram-negative organisms coupled with an alarming scarcity
of new antibiotic classes has forced the healthcare community
to optimize the therapeutic potential of currently available
antibiotics [3].
β-Lactams, the most commonly prescribed class of antibi-
otics, are routinely recommended as the first-line therapy in
many treatment guidelines [4]. Piperacillin/tazobactam is a β-
lactam/β-lactamase inhibitor combination with in vitro activ-
ity against a broad spectrum of aerobic and anaerobic and
Gram-positive and Gram-negative bacteria [5, 6].
Piperacillin/tazobactam is approved by the U.S. Food and
Drug Administration (FDA) for the treatment of HAP and
ventilator-associated pneumonia (VAP) [7]. For β-lactam
agents, the fraction of the dosing interval during which the
free drug concentrations are above the bacterial minimum in-
hibitory concentration (fT>MIC) is the pharmacodynamic
(PD) index that best links drug exposure with the antibacterial
effect [8]. The recommended dose for HAP is 4.5 g every 6 h
(q6h), infused over 30 min, in combination with an aminogly-
coside [9]. With intermittent infusion (II), β-lactams attain a
high peak concentration, but a short half-life (t1/2) can lead to
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precipitous drops in plasma drug levels and a suboptimal
fT>MIC [10]. The administration of antibiotics as a prolonged
(extended or continuous) infusion has been proposed as a way
to optimize pharmacokinetics (PK), resulting in more consis-
tent plasma drug levels and maximizing fT>MIC, particularly
for bacteria with high MIC values [11–13]. Compared with
bolus dosing, increased bacterial killing is seen both in vitro
and in vivo with prolonged infusions [14, 15]. In silicomodels
suggest that exposures produced by prolonged infusions gen-
erate a greater probability of target attainment than those
attained with bolus dosing [16]. However, it is unclear wheth-
er prolonged infusions of β-lactams could translate into better
clinical cure or survival.
Some studies noted that clinical advantage was observed
for prolonged infusion β-lactams [17–19]. Several trials to
date comparing clinical cure or survival of prolonged/
continuous infusion of β-lactams with II have been complet-
ed, with conflicting results [20]. A recent review summarized
the evidence regarding the comparative effectiveness of
prolonged versus short-term infusion of piperacillin/tazobac-
tam, but did not synthesize the available data [21]. Most of
these studies were limited to severely ill patients. We wish to
add our experience with extended infusion (EI) and II of
piperacillin/tazobactam in critically ill patients with low ill-
ness severity to the picture presented in the above-mentioned
research. As a result, we performed a randomized, open-label,
comparative clinical trial, intending to establish the clinical
efficacy, PK, and pharmacoeconomic parameters of
piperacillin/tazobactam administered by EI compared with II
in the treatment of critically ill patients with low illness sever-
ity with HAP in China.
Materials and methods
Study design
This randomized, parallel study was conducted at the inten-
sive care unit (ICU) of Tianjin Medical University Cancer
Institute and Hospital, Tianjin, China. The study protocol
and informed consent form were reviewed and approved by
the Ethics Committee of Tianjin Medical University Cancer
Institute and Hospital. This study was identified on
ClinicalTrials.gov as study NCT01796717. Consent to partic-
ipate was obtained from patients.
Patients
Eligible subjects included those diagnosed of HAP based on
the guidelines of the American Thoracic Society/Infectious
Diseases Society of America (ATS/IDSA) [7]. All of them
were aged between 18 and 70 years. Patients were excluded
from entry into the study if they had severe pyemia with
hypotension or/and evidences of failure of organ function
(shock: systolic pressure <90 mmHg or diastolic pressure
<60 mmHg, requiring more than 4 h of administration of
vasopressor agents; renal impairment: urine volume
<20 mL/h or <80 mL/4 h after excluding any other potentials;
acute renal failure requiring dialysis; creatinine clearance
(CLcr) <40 mL/min). Other exclusion criteria were: docu-
mented infection caused by pathogens beyond the antibacte-
rial spectrum of piperacillin/tazobactam; previously diag-
nosed repeated lung infection (e.g., bronchial obstruction, ob-
structive pneumonia, pulmonary abscess, empyema, and ac-
tive tuberculosis); history of allergy to penicillins; pregnancy
or breast-feeding women.
Drug administration and blood sampling
Randomization was stratified by the institution with 1:1 al-
location to each arm. Following study enrollment, an un-
blinded research nurse or pharmacist was responsible for
the preparation of the blinded medications; the allocation
status was determined by opening a sequentially numbered
sealed envelope. Patients were randomized to receive
piperacillin/tazobactam 4/0.5 g administered either over
30 min every 6 h as the II group or 3 h every 6 h as the
EI group using a syringe pump via a central venous catheter.
The two dosing regimens provided equivalent total daily
doses and the duration was 7–14 days. Blood samples of
4 mL were collected through intravenous access at the ad-
ministration of the first dose. Time points designated for
plasma drug concentration determinations were time zero
(prior to the start of administration) and at 0.5, 1, 2, 3, 4,
and 6 h after the start of the infusion. The samples were
collected into heparinized tubes and centrifuged at
3000 rpm (4 °C) for 5 min, which were then divided into
two aliquots and stored at −80 °C for later analysis.
Drug assay
Plasma piperacillin and tazobactam concentrations were
measured using high-performance liquid chromatography
(HPLC), as described previously [16]. The assays were fully
validated for specificity, calibration model, accuracy and
precision, recovery, and stability according to the FDA guid-
ance of bioanalytical method validation [22]. The standard
curve was linear over the concentration ranges 0.1–500 mg/
L (r2 > 0.999) for piperacillin and 0.1–200 mg/L (r2 > 0.999)
for tazobactam, respectively. There were three quality con-
trols for each standard curve in order to ensure assay accu-
racy. The within- and between-batch accuracy were within
15 % at high, medium, and low concentrations for both
drugs. For piperacillin, the within-day (n = 5) coefficient of
variation (CV) for spiked plasma control specimens of 0.2,
10, and 250 mg/L were 10.7, 8.1, and 4.6 %, respectively,
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and the between-day (n = 5) CV were 7.3, 6.5, and 3.9 %.
For tazobactam, the within-day (n = 5) CV for spiked plasma
control specimens of 0.2, 10, and 100 mg/L were 11.6, 5.8,
and 6.3 %, respectively, and the between-day (n = 5) CV
were 9.8, 3.3, and 4.2 %. Stability tests (including short-
term temperature stability, long-term stability, freeze and
thaw stability, and post-preparative stability) indicated that
piperacillin and tazobactam remained stable and no detect-
able loss or degradation was observed.
The plasma concentrations versus time data were analyzed
using non-compartmental methods. The DAS 2.1 PK analysis
system (Anhui, China) was used to assess the PK parameters.
The time to peak plasma concentration (Tmax) and peak plas-
ma concentration (Cmax) were obtained. The elimination half-
life (t1/2) was calculated as 0.693/Zeta (Zeta is the slope of the
terminal phase). The area under the concentration–time curve
(AUC) from zero to infinity (AUC0-∞) was equivalent to the
sum of the areas from time zero to the time of the last mea-
sured concentration, calculated by using the linear trapezoidal
method (until Cmax), the log-trapezoidal method (until the last
measurable concentration), and the extrapolated area. The ex-
trapolated area was determined by dividing the final measured
concentration by the slope of the terminal log-linear phase.
Total body clearance (CL) was calculated as dose/AUC0-∞.
The area under the moment curve from zero to infinity
(AUMC0-∞) was calculated using the linear trapezoidal rule
and the mean residence time (MRT) was calculated as
AUMC0-∞/AUC0-∞.
Assessment of efficiency and safety
Clinical response was assessed daily by recording clinical
signs and symptoms, white blood cell (WBC) count, and body
temperature until it was normalized and again at the end of
treatment. Clinical outcome definitions after study drug ces-
sation, including clinical success and clinical failure, are
shown in Table 1. The MIC was done according to the
Clinical and Laboratory Standards Institute (CLSI) standard.
The percentage of the dosing interval during which the free
drug concentration exceeded the pathogen MIC (%fT>MIC)
and four times the MIC (%fT>4×MIC) for individual patients
was calculated for MICs of 4, 8, and 16 mg/L. The %fT>MIC
and %fT>4×MIC at each MIC were calculated by using the
PK parameters of piperacillin determined for each patient. We
used an MIC of 16 mg/L as the clinical breakpoints for
Pseudomonas aeruginosa, as defined by the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST). As the drug concentration measured in this study
by the HPLC method represented total (bound plus free) drug,
the free drug concentration was calculated by measured the
total drug concentration ×70 % [23]. Patients were monitored
throughout the study for adverse events. Physical examination
and laboratory evaluations were processed to confirm the
presence or absence of chemical or hematological adverse
events resulting from the drug.
Pharmacoeconomic analysis
The costs associated with drug acquisition, preparation, ad-
ministration process (including pharmacy preparation time,
nursing time, cost of materials required for the drug prepara-
tion and administration, maintenance of the intravenous, site
as well as waste disposal), concomitant antibiotics, and plas-
ma drug concentration measurement using HPLC were com-
pared in both groups.
Statistical analysis
A sample of 50 patients was calculated to achieve a power of
85 % to detect a 20 % absolute difference in the expected
outcome at a significance level of 10 %. Statistical analysis
was performed using SPSS version 12.0 (SPSS Inc., Chicago,
IL, USA). Quantitative variables were reported as mean and
standard deviation. Comparisons between groups were per-
formed using the Student’s t-test. Qualitative variables were
reported as frequencies or percentages. The Mann–Whitney
U-test was used to compare the demographic and clinical
characteristics between the extended and intermittent treat-
ment groups. Success rates were analyzed by Fisher’s exact
test. The incidence of adverse events was compared by
Fisher’s exact test. All statistical tests were two-tailed, and a
value of p < 0.05 was considered to be statistically significant.
The analyst was blinded to the EI or II groups.
Results
Fifty-two patients were enrolled into the study, whereas two
were withdrawn for different reasons: one patient withdrew
informed consent and in the other patient, creatinine clearance
diminished severely after study enrolment. Fifty patients com-
pleted the study, with 25 patients randomized to the EI group
and 25 patients randomized to the II group. The baseline clin-
ical characteristics of the study population are presented in
Table 2. No statistically significant differences were found
Table 1 Clinical outcome definitions after study drug cessation
Clinical response Definition
Clinical success 1. Cure or improvement of all signs and symptoms
caused by the infection
2. No additional antibiotic therapy required
Clinical failure 1. Persistent or worsening of any one of the
clinical symptoms
2. New clinical signs and symptoms of infection
3. Other systemic antimicrobial therapy required
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between the two groups in terms of age, body weight, body
mass index (BMI), identified pathogens, CLcr, Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score, Clinical Pulmonary Infection Score (CPIS), or
procalcitonin (PCT) after bivariate analysis was performed.
Similar numbers of patients in the two groups received con-
comitant antibiotic therapy: 3 (12 %) in the EI group and 4
(16 %) in the II group. In the continuous-infusion group,
Table 2 Demographic and
clinical characteristic of patients
with hospital-acquired
pneumonia (HAP) treated with
piperacillin/tazobactam







Mean ± S.D. 69.75 ± 5.97 67.04 ± 7.79
Median (range) 71 (56–82) 71 (56–80)
Sex, n (%)
Male 14 (56) 15 (60)
Female 11 (44) 10 (40)
Body weight, kg
Mean ± S.D. 67.12 ± 8.22 66.3 ± 8.86
Median (range) 68.5 (55.0–80.5) 65.0 (53.0–81.5)
BMI, kg/m2
Mean ± S.D. 23.67 ± 3.73 22.17 ± 1.79
Median (range) 21.5 (16.3–27.9) 20.4 (17.5–30.2)
Diagnosis, n (%)
Hypertension 8 (32) 12 (48)
Cardiac surgery 5 (20) 4 (16)
Cardiological 1 (4) 2 (8)
Diabetes 7 (28) 10 (40)
Tuberculosis 0 (0) 0 (0)
Infection site, n (%)
Lung 10 (40) 8 (32)
Intra-abdominal 5 (20) 9 (36)
Urinary tract 6 (24) 5 (20)
Skin and soft tissue 4 (16) 3 (12)
Identified pathogens, n (%)
Pseudomonas aeruginosa 8 (32) 5 (20)
Escherichia coli 7 (28) 8 (32)
Klebsiella pneumoniae 7 (28) 9 (36)
Enterobacter cloacae 2 (8) 1 (4)
Serratia marcescens 1 (4) 2 (8)
CLcr, mL/min (range) 73 (47–251) 79 (53–278)
Concomitant antibiotic, n (%) 3 (12) 4 (16)
APACHE II score
Mean ± S.D. 23.17 ± 7.10 23.73 ± 6.73
Median (range) 18 (10–35) 20 (9–35)
CPIS
Mean ± S.D. 7.17 ± 1.05 7.46 ± 1.30
Median (range) 7 (4–8) 7 (4–10)
PCT (μg/L)
Mean ± S.D. 5.51 ± 1.63 3.99 ± 0.98
Median 3.31 3.56
All patients were Asian
S.D. standard deviation, BMI body mass index, CLcr creatinine clearance, APACHE Acute Physiology and
Chronic Health Evaluation II, CPIS Clinical Pulmonary Infection Score, PCT procalcitonin
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concomitant agents were aminoglycosides or vancomycin. In
the intermittent-infusion group, concomitant agents were
levofloxacin, ciprofloxacin, and metronidazole, in addition
to aminoglycosides and vancomycin.
Plasma drug concentration sampling and PK analyses
were completed on all study patients. The PK parame-
ters of piperacillin are described in Table 3. Peak plas-
ma concentrations of piperacillin are attained immediate-
ly after the completion of an intravenous infusion in the
II group, and 2.7 ± 0.3 h after the start of infusion in the
EI group. The mean peak plasma concentrations of pi-
peracillin in the 30-min infusion group and the 3-h in-
fusion group were 284.29 and 91.38 mg/L, respectively.
Following administration, the plasma t1/2 of piperacillin
ranged from 0.8 to 1.4 h.
EI regimens maintained the piperacillin concentration
above a range of MICs and 4×MICs for a greater proportion
of the dosing interval. A trend toward decreasing %fT>MIC
with increasingly elevatedMICswas observed. Infusion of 4 g
of piperacillin, duration of 3 h over every 6 h, resulted in a
mean %fT>MIC of about 100, 98.73, and 93.04 % for organ-
isms with MICs of 4, 8, and 16 mg/L, respectively.
Administration of 4 g of piperacillin for 30 min every 6 h
resulted in a mean %fT>MIC of about 81.48, 53.29, and
42.15 % for MICs of 4, 8, and 16 mg/L, respectively.
Significant differences in %fT>MIC and %fT>4×MIC were
noted when doses were administered over an extended 3-h
infusion compared with the standard 30-min infusion time
evaluated in this clinical study (p < 0.01, Table 4).
The total cost per patient in the ICU was lower in the
EI group than the II group ($1351.72 ± 120.39 vs.
$1782.04 ± 164.51, p = 0.001). There was no significant
difference in the clinical failure rate between the EI and
II groups (12.0 vs. 20.0 %). Furthermore, the higher prob-
ability of clinical success rate of HAP was not found by
EI of piperacillin/tazobactam than by II (Table 5). There
was no mortality among patients with HAP, irrespective of
the MIC.
There was no significant difference in the safety and
tolerability of both treatment groups. The incidence of
study drug-related adverse events was experienced approx-
imately by 19 (76.0 %) patients in the EI group and 23
(92.0 %) patients in the II group. Those observed drug-
related adverse events with a frequency of 1 % or more in
both treatment groups are presented in Table 6. The types
and severity of adverse events were similar for both
groups, with the most common adverse events being gas-
trointestinal disorders, including diarrhea, nausea, and
vomiting. Other adverse effects in both treatment groups
included hypokalemia, hypocalcemia, γ-glutamyltransferase
increased, aspartate aminotransferase increased, alanine
aminotransferase increased, thrombocythemia, eosinophil
count increased, and fever, which were mild to moderate
in severity. Five patients in the EI group and four patients
in the II group had seriously adverse events, including
renal failure, tachycardia, and confusion. Five patients
withdrew from the study due to adverse events: two in
the EI group (one due to a treatment-related adverse
event) and three in the II group (two due to treatment-
related adverse events).Table 3 Main pharmacokinetic parameters of piperacillin in HAP
patients after intravenous administration. Values are expressed as mean
± standard deviation (S.D.)
Parameters Extended infusion Intermittent infusion p-Value
AUC0-t (mg·h/l) 288.25 ± 47.28 433.25 ± 69.23 0.0014
AUC0-∞(mg·h/l) 296.91 ± 39.04 442.72 ± 43.35 <0.0001
MRT0-t (h) 2.50 ± 0.31 1.55 ± 0.20 0.0002
t1/2 (h) 1.19 ± 0.27 1.08 ± 0.19 0.3765
Tmax (h) 2.7 ± 0.3 0.5 ± 0.0 <0.0001
CL (L/h) 13.47 ± 1.28 9.04 ± 0.72 <0.0001
Cmax (mg/l) 91.38 ± 20.35 284.29 ± 35.73 <0.0001
AUC area under the concentration–time curve,MRTmean residence time,
t1/2 half-life, Tmax time to maximum plasma concentration, CL clearance,
Cmax maximum observed concentration







%fT>MIC (mean ± S.D.) 4 100 ± 0 81.48 ± 3.97
8 98.73 ± 2.31 53.29 ± 8.23
16 93.04 ± 6.51 42.15 ± 5.56
%fT>4×MIC (mean ± S.D.) 4 94.29 ± 8.26 40.31 ± 4.18
8 87.02 ± 9.70 36.35 ± 6.48
16 73.65 ± 6.29 29.73 ± 4.21
MIC minimum inhibitory concentration, %fT>MIC and %fT>4×MIC
percentage of the dosing interval during which free drug concentration
exceeded pathogen MIC and four times the MIC
Table 5 Clinical outcomes of patients with HAP receiving extended or
intermittent infusions of piperacillin/tazobactam
Characteristic Extended
infusion (n = 25)
Intermittent
infusion (n = 25)
Clinical success rate, n (%) 22/25 (88.0) 20/25 80.0)
Clinical failure rate, n (%) 3/25 (12.0) 5/25 (20.0)
Total cost per patient in ICU, $
Mean ± S.D. 1351.72 ± 120.39 1782.04 ± 164.51
Median 1066.17 1387.60
ICU intensive care unit
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Discussion
This randomized, open-label, comparative clinical trial was
conducted in patients with HAP who received piperacillin/
tazobactam via EI or II. Differently from studies published
previously, the study presented here focused upon low illness
severity patients rather than severely ill patients. To the best of
our knowledge, this report is the largest study describing the
PK, PD, clinical efficiency, and pharmacoeconomics of pa-
tients treated with either EI or II of piperacillin/tazobactam
in China. In this study, EI or II had no impact on adequacy
of treatment, although the EI group resulted in sufficient plas-
ma concentrations. The results indicated that EI was as effec-
tive as conventional II.
A population PK study by Bulitta et al. reported that the
administration of piperacillin/tazobactam by EI may be phar-
macodynamically advantageous over II because the
%fT>MIC is higher by EI [24]. The results of Monte
Carlo simulations suggested that changing medical practice
from bolus dosing to EI would improve target attainment
rates dramatically for organisms with an MIC ≤16 mg/L
[16]. Rafati et al. performed a study of 40 septic critically
ill patients who received piperacillin by EI (2 g over 0.5 h as
a loading dose, followed by 8 g daily over 24 h) or II (3 g
every 6 h over 0.5 h). In this study, the authors found that
the %T>MIC was higher by EI (100 %) than by II (62 %)
when the MIC was 16 mg/L [25]. Another study conducted
by De Waele et al. found that EI piperacillin/meropenem
was associated with an improvement in target attainment in
critically ill patients. However, a 100 % fT>MIC target is
not reached in a significant proportion of these patients with-
out renal dysfunction [26].
Some in vitro and animals in vivo studies on β-lactams
have indicated that %fT>MIC is crucial for therapeutic suc-
cess [9]. A recent retrospective analysis of the cephalosporin
antibiotics cefepime and ceftazidime is the first data correlat-
ing PK/PD data with clinical outcome for patients. The au-
thors found significantly improved clinical outcome when
%fT>MIC was maintained [27]. PD modeling had also sug-
gested a potential benefit of extended or continuous infusion
of β-lactams antibiotics in clinical outcome, but this was
especially noted for bacteria with high MICs, in whom con-
ventional II may fail to achieve the PD target [25]. However,
experimental studies suggested that increasing drug concen-
trations up to five times theMIC ormore (%fT>5×MIC) could
further optimize the bactericidal activity [15]. However, the
optimum β-lactam strategy (%fT>MIC or %fT>4–5×MIC)
has not yet been identified for human infections, and the
threshold of efficacy is even more controversial when EI is
processed [28].
In the present study of HAP patients with low illness se-
verity, piperacillin/tazobactam administered by EI was more
likely to enable better achievement of %fT>MIC. However,
our results demonstrated that this approach did not translate
into better patient outcomes. From our research, the clinical
success rate and clinical failure rate were similar between
groups. Drug-related adverse effects were mild to moderate
and similar to studies reported in both treatment arms in other
studies [29, 30]. Several observational studies with varying
study designs comparing the clinical benefits of prolonged
and intermittent infusion of β-lactam antibiotics have been
conducted, with inconsistent results. A DALI study conducted
across 68 hospitals revealed that infected critically ill patients
may have adverse outcomes as a result of inadequate antibi-
otic exposure, and a paradigm change to more personalized
antibiotic dosing may be necessary to improve outcomes for
thesemost seriously ill patients [31]. A recent study conducted
in India suggested that there was no significant difference in
the clinical outcomes of patients receiving piperacillin/
tazobactam via EI or II when measured by serial CPIS [32].
In a retrospective cohort study of piperacillin/tazobactam in
adults with VAP caused by Gram-negative pathogens, in-
creased clinical cure was demonstrated with MICs >8 mg/L
by continuous versus intermittent infusion [29]. The results
from another retrospective cohort study showed a significant-
ly lower 14-day mortality rate by EI in patients with
Pseudomonas aeruginosa sepsis [33]. A third retrospective
cohort study, however, failed to demonstrate any improved
clinical outcomes with EI of piperacillin/tazobactam [30].
The pharmacoeconomic study was specific to piperacillin/
tazobactam to determine the drug supply and total labor costs
associated with the acquisit ion, preparation, and
Table 6 Drug-related adverse
events in patients with HAP in
either treatment group
Adverse events Extended infusion
(n = 25), n (%)
Intermittent infusion
(n = 25), n (%)
p-Value
Gastrointestinal disorders 2 (8) 3 (12) 0.637
Hypokalemia 1 (4) 2 (8) 0.552
Hypocalcemia 1 (4) 3 (12) 0.297
γ-Glutamyltransferase increased 1 (4) 2 (8) 0.552
Aspartate aminotransferase increased 3 (12) 2 (8) 0.637
Alanine aminotransferase increased 2 (8) 1 (4) 0.552
Thrombocythemia 1 (4) 3 (12) 0.297
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administration of continuous and intermittent infusion regi-
mens. Our analysis revealed that drug acquisition costs
accounted for the majority of the total costs, and nursing time
accounted for the largest percentage of the labor costs for both
groups. In this study, EI of piperacillin/tazobactam enabled
savings of about $430.32/patient to be made. Compared with
II, EI was a less costly method of administration. The use of EI
for the administration of β-lactams maximizes the %fT>MIC,
allowing the use of less drug to maintain concentrations above
the MIC and can decrease drug and labor consumption, lead-
ing to cost savings. In a prospective, open-label, controlled
study by Grant et al., 98 hospitalized patients were random-
ized to receive piperacillin by continuous (12/1.5 g per day) or
intermittent infusion (3/0.375 g every 6 h or 4/0.5 g every 8 h)
for HAI. The authors found lower costs per patient ($399
± 407 vs. $523 ± 526, p = 0.028) encompassing all costs direct-
ly related to antibiotic use (drug, preparation, treatment of
adverse events, and concomitant antibiotics) [34]. A study of
patients with Pseudomonas aeruginosa pneumonia suggested
that EI of piperacillin/tazobactam enabled savings of the total
daily cost of the antimicrobial by US$25–50, representing a
saving of $70,000–135,000 per year on direct drug acquisition
costs compared with II [33]. Results were reported in a recent
study in which €15/day was saved in patients with VAP using
therapeutic drug monitoring [35]. A recent research conducted
by Brunetti et al. suggested that automatic substitution of EI
for II piperacillin/tazobactam is safe and associated with sig-
nificant cost savings. They found that the total cost per treat-
ment course was reduced in the EI group by 13 % compared
with the II group [36].
The findings of the present study demonstrated that the EI
group allowed statistically lower costs compared with the II
group. With the increasing interest in EI of β-lactams and the
existing fiscal restraints of the healthcare system in China,
further research is needed to fully analyze the pharmacody-
namics, clinical efficiency, and pharmacoeconomics, in order
to treat infections in both clinically sound and cost-effective
fashions.
Our study has several limitations that should be taken into
account when interpreting the results. First, the study design
was single-blinded and it would have been enhanced by dou-
ble-blinding. Second, it was a single-center study with limited
sample size, limiting the applicability of the results to other
ICUs; however, a pilot study was conducted to obtain prelim-
inary data for additional studies with larger cohorts of patients.
Third, this single-center study only included patients with
normal renal function, which limits extrapolation of these
findings to all ICU patients. Fourth, we did not investigate
free drug concentrations because of the relatively low protein
binding of piperacillin [23]. Instead, total drug concentrations
were measured with correction for protein binding based on
the literature [37]. However, changes in protein and albumin
levels that occur in ICU patients may lead to unpredictable
alterations in the free fraction of the drug that is active at the
site of infection. Finally, some of the patients did not receive
piperacillin/tazobactam as monotherapy and, consequently,
the reported data may have been the results of a synergistic
effect with other antimicrobials. Despite these limitations, the
results of our study may contribute to an interest in the use of
β-lactam antibiotics by EI. In order to achieve a more com-
prehensive and uniform database, a prospective, multi-center,
double-blinded, comparative study is needed.
In conclusion, in this randomized, open-label, comparative
study for the treatment of HAP in critically ill patients with
low illness severity, the use of EI as a means of administering
piperacillin/tazobactam maximized %fT>MIC and was more
cost-effective than II of the drug. The clinical efficiency of
piperacillin/tazobactam was independent of the mode of ad-
ministration, either continuous dosing or intermittent dosing.
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